Stock Transactions	9 Months Ended
Jun. 30, 2016
Notes to Financial Statements
Stock Transactions	NOTE 11. STOCK TRANSACTIONS BIO- MATRIX SCIENTIFIC GROUP, INC.: On May 6, 2016 the Company issued 287,138,354 of its Common Shares in satisfaction of $28,713 of convertible indebtedness. REGEN BIOPHARMA, INC. Common Stock On May 9, 2016 Regen issued 700,000 of its Common Shares in satisfaction of $14,000 of principal indebtedness. On May 23, 2016 Regen issued 1,000,000 of its Common Shares for cash consideration of $12,500. On June 6, 2016 Regen issued 3,500,000 of its Common Shares for cash consideration of $118,750. On June 15, 2016 Regen issued 1,095,000 of its Common Shares for cash consideration of $13,687. Series A Preferred Stock On April 7, 2016 Regen issued 1,000,000 shares of its Series A Preferred stock in satisfaction of $10,000 of principal indebtedness. On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to David Koos, Regen’s Chief Executive Officer, as consideration for efforts expended by Koos with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate.. On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Harry Lander , Regen’s President and Chief Scientific Officer, as consideration for efforts expended by Lander with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate. On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Todd Caven , Regen’s Chief Financial Officer, as consideration for efforts expended by Caven with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate On May 23, 2016 Regen issued 3,000,000 shares of its Series A Preferred stock for cash consideration of $37,500. On June 6, 2016 Regen issued 5,500,000 shares of its Series A Preferred stock for cash consideration of $106,250. On June 15, 2016 Regen issued 3,285,000 shares of its Series A Preferred stock for cash consideration of $41,062.

Stock Transactions

9 Months Ended

Jun. 30, 2016

NOTE 11. STOCK TRANSACTIONS

BIO- MATRIX SCIENTIFIC GROUP, INC.:

On May 6, 2016 the Company issued 287,138,354 of its Common Shares in satisfaction of $28,713 of convertible indebtedness.

REGEN BIOPHARMA, INC.

Common Stock

On May 9, 2016 Regen issued 700,000 of its Common Shares in satisfaction of $14,000 of principal indebtedness.

On May 23, 2016 Regen issued 1,000,000 of its Common Shares for cash consideration of $12,500.

On June 6, 2016 Regen issued 3,500,000 of its Common Shares for cash consideration of $118,750.

On June 15, 2016 Regen issued 1,095,000 of its Common Shares for cash consideration of $13,687.

Series A Preferred Stock

On April 7, 2016 Regen issued 1,000,000 shares of its Series A Preferred stock in satisfaction of $10,000 of principal indebtedness.

On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to David Koos, Regen’s Chief Executive Officer, as consideration for efforts expended by Koos with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate..

On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Harry Lander , Regen’s President and Chief Scientific Officer, as consideration for efforts expended by Lander with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate.

On April 7, 2016 Regen Biopharma, Inc. (“Regen”) issued 10,000,000 shares of Regen’s Series A Preferred Stock (“Shares”) to Todd Caven , Regen’s Chief Financial Officer, as consideration for efforts expended by Caven with regards to addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to Regen’s Investigational New Drug Application for HemaXellerate

On May 23, 2016 Regen issued 3,000,000 shares of its Series A Preferred stock for cash consideration of $37,500.

On June 6, 2016 Regen issued 5,500,000 shares of its Series A Preferred stock for cash consideration of $106,250.

On June 15, 2016 Regen issued 3,285,000 shares of its Series A Preferred stock for cash consideration of $41,062.